The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics

Mizrahi, Romina; Mamo, David C.; Rusjan, Pablo; Graff, Ariel; Houle, Sylvain; Kapur, Shitij

doi:10.1017/s1461145709000327

Cited by 56 publications

(50 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with Mizrahi et al [38], this study showed that aripiprazole increased subjective well-being and hedonia more than a strong DA antagonist [33]. Moreover, aripiprazole has also shown good treatment effects on depression and bipolar disorder [39,40], and the same receptor effects may alleviate or stabilize (an)hedonic mood [40].…”

Section: Discussionsupporting

confidence: 84%

An Open Randomized Pilot Trial on the Differential Effects of Aripiprazole versus Risperidone on Anhedonia and Subjective Well-Being

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 84%

An Open Randomized Pilot Trial on the Differential Effects of Aripiprazole versus Risperidone on Anhedonia and Subjective Well-Being

et al. 2011

View full text Add to dashboard Cite

show abstract

“…from risperidone or olanzapine showed improvement in their subjective well-being despite very high levels of D 2 occupancy (Mizrahi et al, 2009). The lack of significant changes in negative symptoms following amisulpride administration may be related to its limbic selectivity (Bressan et al, 2003) and fast dissociation [42 s for 4 nmol/l S-(-)-amisulpride] (Seeman, 2005).…”

Section: Discussionmentioning

confidence: 99%

No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol

Park

Yang

et al. 2012

International Clinical Psychopharmacology

View full text Add to dashboard Cite

Noncompliance and poor outcome in patients with schizophrenia are closely related to the negative symptoms secondary to antipsychotics. No controlled study has evaluated whether amisulpride and aripiprazole induce negative symptoms. The aim of this study was to assess the effects of single doses of amisulpride, aripiprazole, haloperidol, and risperidone in healthy volunteers. Seventy-eight young volunteers took part in this double-blind, randomized, placebo-controlled, parallel study of four antipsychotics: 400 mg amisulpride, 10 mg aripiprazole, 3 mg haloperidol, and 2 mg risperidone. Assessments of negative symptoms were done 4 h after administration using both subjective rating scales (Neuroleptic Induced Deficit Syndrome Scale and Subjective Deficit Syndrome Scale) and an objective rating scale (Scale for the Assessment of Negative Symptoms). Risperidone only produced significant increases on the avolition score of the Neuroleptic Induced Deficit Syndrome Scale and blunted affect and alogia scores of the Scale for the Assessment of Negative Symptoms compared with placebo. The effect on blunted affect persisted after controlling for mental sedation. Amisulpride, aripiprazole, and haloperidol did not induce negative symptoms. Aripiprazole and risperidone induced mild extrapyramidal symptoms. The most common adverse events were somnolence and cognitive slowing. These data indicate that a single risperidone dose induces negative symptoms in normal volunteers, whereas amisulpride, aripiprazole, and haloperidol do not. These characteristics of antipsychotics should be considered when choosing optimal drugs for patients with psychosis.

show abstract

“…Previous studies have suggested that the partial dopamine agonistic properties of aripiprazole, as opposed to the dopamine antagonistic properties of other antipsychotics, have a more favorable effect on subjectively experienced side effects [Liemburg et al 2011;Mizrahi et al 2009;Ohlsen and Pilowsky, 2005]. These studies, however, lack ecological validity because emotional experiences were assessed retrospectively and globally using cross-sectional instruments.…”

Section: Discussionmentioning

confidence: 99%

Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports

Lataster

Myin-Germeys

Wichers

et al. 2011

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Abstract:Background: Blockade of the dopamine D 2 receptor is a key mechanism in the antipsychotic treatment of patients with a psychotic disorder, but may also induce emotional deficits. The partial D 2 agonistic profile of aripiprazole has, therefore, been suggested to favor emotional wellbeing compared with the pure dopamine antagonistic properties of traditional antipsychotics. Method: The current study used the experience sampling method (a structured diary technique) to assess the effects of switching from treatment with traditional dopamine antagonist antipsychotics to treatment with the partial dopamine agonist aripiprazole on emotional wellbeing in the daily life of 13 patients with a diagnosis of schizophrenia. Results: More than half of all patients experienced exacerbation of psychotic symptoms after they had switched to the aripiprazole medication regime, consequently resulting in dropout of the study. Furthermore, switching to aripiprazole treatment, when effective in terms of symptom reduction, was accompanied by decreased feelings of both positive and negative affect in daily life, suggestive of a general state of emotional dampening. Conclusions: Although the scale of the current study and the 54% dropout rate call for careful interpretation of the data, implementation of ecological monitoring in psychopharmacological research may open up new avenues for untangling the working mechanisms of compounds with regard to their impact on mental states.

show abstract

The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics

Cited by 56 publications

References 33 publications

An Open Randomized Pilot Trial on the Differential Effects of Aripiprazole versus Risperidone on Anhedonia and Subjective Well-Being

An Open Randomized Pilot Trial on the Differential Effects of Aripiprazole versus Risperidone on Anhedonia and Subjective Well-Being

No negative symptoms in healthy volunteers after single doses of amisulpride, aripiprazole, and haloperidol

Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports

Contact Info

Product

Resources

About